Close Menu

10X Genomics

 

10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.

 

10X Genomics Company Profile  

 

President & CEO: Serge Saxonov

CEO photo:

 10X Genomics CEO photo - Serge Saxonov

Website: http://10xgenomics.com

Headquarters: Pleasanton, CA

10x Genomics employees: 101-250

Funding: $113M USD

Founded: 2012

Founders: Serge Saxonov, Ben Hindson


 

10x Genomics News 

Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.

Researchers from Wellcome Sanger Institute and elsewhere found that the immune landscape of the kidney is zoned to counter dominant immunological challenges.

Industry experts say a receptive market and investor interest in new technologies have spurred the increase in genomics tools and molecular diagnostics IPOs. 

10x CEO and Cofounder Serge Saxonov reflected on how the firm's IPO got so big and how he plans to make the single-cell analysis firm even bigger.

A study published this week describing the new approach shows higher resolution than an earlier method that 10x Genomics is commercializing.

The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.

he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.

In response to BD's patent suit, 10x alleged BD's single-cell products infringe its own patents. 10x also asked the judge to dismiss BD's lawsuit.

The single-cell sequencing firm originally said it was looking to raise $100 million in its initial public offering.

Pages

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.